NewBiologix SA is a biotechnology company innovating Swiss-engineered solutions and technologies for gene and cell therapy production. The company combines a specialized focus in this field with deep expertise in cell line engineering. NewBiologix addresses gene therapy production limitations with its full suite of advanced cell lines and the Xcell™ Portfolio, a set of technologies designed to provide in-depth insights into rAAV quality. By enabling partners to produce more reliable, safer gene therapies faster and at scale, the company is shaping the future of patient health.
“As CEO and co-founder of NewBiologix, I am proud to launch our new company of incredibly talented, intelligent, and entrepreneurial individuals who are deeply dedicated to advancing novel technologies that will revolutionize the gene and cell therapy landscape.
By filling the innovation gap to meet the rising demand for economically viable, large-scale production of viral vectors for gene therapy, NewBiologix is poised to assist partners in developing advanced therapy medicinal products (ATMPs) addressing rare, chronic, and incurable diseases.
We are challenging the manufacturing status quo – aware that real change comes from disruptive and transformative technologies, not from relying on legacy processes and technologies. In developing our groundbreaking DNA integration platform for the advanced engineering of human and mammalian cell lines, NewBiologix will win through science and innovation.
My challenge every day is to inspire and encourage our extraordinary team at NewBiologix to think and act differently! Our optimism for what we can accomplish is boundless, and our passion for our customers and patients is unmatched.”
We are assembling a network of leading experts, partners and top talent to support our ambitious goal.
